Trials / Completed
CompletedNCT05295940
A Study of LY3841136 in Healthy and Overweight Participants
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3841136 in Healthy and Overweight Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and may last up to 14 and 28 weeks for each participant and may include 7 and 19 visits in parts A and B, respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3841136 | Administered SC. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2022-03-30
- Primary completion
- 2024-01-25
- Completion
- 2024-01-25
- First posted
- 2022-03-25
- Last updated
- 2024-04-01
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05295940. Inclusion in this directory is not an endorsement.